1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsParkinson's Research Program (PRP) Early Investigator Research Award – Funding Level 2 is sponsored by Congressionally Directed Medical Research Programs (CDMRP) - Department of Defense. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Congressionally Directed Medical Research Programs -- Parkinson’s Research Program -- Early Investigator Research Award | Research Funding Congressionally Directed Medical Research Programs -- Parkinson’s Research Program -- Early Investigator Research Award The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers.
The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.
The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.
• Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required.
• Funding Level 2: Mentor not required. Preliminary data are required. Required Pre-Application Submission Deadline: Oct.
23, 2026 Application Submission Deadline: Nov.
6, 2026 All applications must address at least one of the following FY26 PRP Focus Areas: • Understanding how Parkinson’s disease biological and clinical heterogeneity impacts disease presentation, clinical course and therapeutic outcomes, from prodromal to late-stage Parkinson’s disease • Development and characterization of in vitro model systems that approximate in vivo cellular and system complexity • Biological mechanisms or biomarkers, such as clinical, fluid, imaging, tissue, and devices, of unmet medical needs that could lead to the development of treatments for PD.
Applications can utilize laboratory models through to human participants. • Interventions that address unmet medical needs of PD that include both clinical and preclinical models.
Postdoctoral fellows, clinical fellows, or independent investigators within 10 years of advanced degree or residency training completion, or equivalent, who are affiliated with an eligible organization are eligible to be named PI on the application, regardless of ethnicity, nationality or citizenship status. • Funding Level 1 applications are intended to support postdoctoral fellows, clinical fellows, or equivalent.
Applications must include at least one mentor who has experience in PD research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. • Funding Level 2 applications are intended to support early-career, independent investigators within 10 years of advanced degree or residency training completion, or equivalent. Applications do not require a mentor.
An investigator may be named on only one FY26 PRP EIRA application as the PI. The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $4. 2M to fund approximately seven Early Investigator Research Award applications with total cost caps of $0.
3M for Funding Level 1 awards and $1. 0M for Funding Level 2 awards. The maximum period of performance is 2 years.
It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Medical - Clinical Science
According to the current listing, eligibility includes: Early-career, independent investigators within 10 years of advanced degree or residency training completion, or equivalent. A mentor is not required. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,000,000 over 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Parkinson's Research Program (PRP) Early Investigator Research Award – Funding Level 2 is funded by Congressionally Directed Medical Research Programs (CDMRP) - Department of Defense. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article